News and Events
Topic: Function and Molecular Mechanism of Protein Arginine Methyltransferase CARM1 in Breast Carcinogenesis
Date: 14/06/2019
Time: 3:30 pm - 4:30 pm
Venue: Room 406, 4/F, Li Ka Shing Medical Sciences Building, Prince of Wales Hospital, Shatin, New Territories
Category: Talks/Seminars

Seminar Poster

Professor Wen Liu
Professor, Minjiang Scholar,
School of Pharmaceutical Sciences,
Xiamen University

About the Speaker:
劉文,「閩江學者」 特聘教授、博士生導師。其主要專注於癌症的表觀遺傳調控分子機制以及應用研究,在此領域取得了一系列具有重要意義的成果,發表多篇高水平研究論文,包括 NatureCellCancer CellMolecular Cell 等;在抗癌小分子 K-80003 方面的研究成果在國際上具有廣泛的影響力,該小分子獲得了美國 FDA 關於其在晚期結直腸癌中開展臨床實驗的批件。劉教授主持多項課題,入選國家自然科學基金 「優秀青年科學基金」 項目和福建省自然科學基金 「傑出青年科學基金」 項目。取得多項榮譽,獲得中國藥學會──賽諾菲青年生物藥物獎和福建省運盛青年科技獎。

While protein arginine methyltransferases (PRMTs) and PRMT-catalysed protein methylation have been well-known to be involved in a myriad of biological processes, their roles in carcinogenesis, particularly in estrogen receptor alpha (ERa)-positive breast cancers, remain incompletely understood. Here we focused on investigating PRMT4 (also called coactivator associated arginine methyltransferase 1, CARM1) in ERa-positive breast cancers due to its high expression and the associated poor prognosis. The team uncovered a “hypermethylation” strategy utilised by enhancer-bound CARM1 in estrogen/ERa-induced gene transcriptional activation, which is critical for the proliferation of ERa -positive breast cancer cells in vitro and tumour growth in mice, suggesting that CARM1 can server as a therapeutic target for breast cancer treatment.

CME Accreditation:
* One CME point for attendance approved by the Medical Council of Hong Kong (MCHK). [ Activity No.: 3650 ]


All are welcome.
For enquiries, please contact Miss Tracy Tang at 3763 6088.